Eye camera spots hidden inflammation in MS patients
NCT ID NCT04289909
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of disease activity. Researchers measured the width of inflammation around retinal vessels, comparing MS patients to controls.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new way to monitor MS activity and progression by looking at the eye, without invasive tests.
- What could go wrong
- This is a small, completed observational study with only 50 participants. It does not test a treatment, so it may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Dec 2020
- Finished
-
Jul 2024
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group 1: * Age between 18 and 60 years old. * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject who has never presented a clinical episode of optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 2: * Age between 18 and 60 years old * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject presenting an acute episode of retrobulbar optic neuritis within 3 months from onset * After optimal treatment for the retrobulbar optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 3: * Age between 18 and 60 years old * Primary or Secondary progressive multiple sclerosis within 10 years of progressive phase; * Affiliation to a social security scheme or beneficiary of such a scheme Group 4 (Healthy Subjects): * Age between 18 and 60 years old * Affiliation to a social security scheme or beneficiary of such a scheme Exclusion Criteria: For all patients (Group 1; 2; 3): * Corticosteroid treatment within one month from inclusion * Other neurological, ophthalmologic or systemic disease; * Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion) * Severe renal dysfunction (glomerular filtration rate \< 30mL/min). This non-inclusion criteria will be verified by serum creatinine test within six months from inclusion; * Contraindication for MRI; * Pregnancy or breast-feeding; * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * Incapacity to understand or sign the consent form; * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty. For healthy subjects (Group 4): * Neurological, ophthalmologic or systemic disease; * Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion); * Contraindication for MRI; * Pregnancy or breast-feeding; * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * Incapacity to understand or sign the consent form; * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Eye diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Under-the-Skin MS drug: can a shot replace an IV drip?
- Can a common antihistamine boost multiple sclerosis treatment?
- Can exercise rebuild muscle and balance in MS?
- Can diet ease the crushing fatigue of multiple sclerosis?
- One-Time CAR-T infusion tested against progressive MS
- Can PET scans reveal hidden brain inflammation in MS?